Topical and systemic antimicrobial agents in burns.
Infection is the major cause of morbidity and mortality in burns. Burn wound infection is defined as burn wound bacterial proliferation in a density equal to or greater than 10(5) bacteria per gram of tissue. Gram-negative bacteria, notably Pseudomonas aeruginosa, as well as staphylococci and fungal opportunists, have been identified as prominent invaders. Topical and systemic antimicrobial agents are essential adjuncts in the prevention and treatment of burn wound infection. Topical antimicrobial therapy is indicated in all hospitalized burn patients. Short-term use of systemic antimicrobials for prophylaxis and treatment is required in all moderate and major burns, specifically for early prophylaxis, perioperative prophylaxis, and clinical infection. Antimicrobial choice is based on specific patient or environmental bacteriological data.
D000287:Administration, Topical; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D002056:Burns / Q000382:microbiology*; D002986:Clinical Trials as Topic; D004756:Enterobacteriaceae Infections / Q000517:prevention & control*; D006801:Humans; D007275:Injections, Intravenous; D011552:Pseudomonas Infections / Q000517:prevention & control*; D011550:Pseudomonas aeruginosa; D013203:Staphylococcal Infections / Q000517:prevention & control*; D013211:Staphylococcus aureus; D013290:Streptococcal Infections / Q000517:prevention & control*; D013297:Streptococcus pyogenes; D014946:Wound Infection / Q000188:drug therapy / Q000517:prevention & control*
D000900:Anti-Bacterial Agents